Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease

被引:24
作者
Bordet, R
Broly, F
Destee, A
Libersa, C
Lafitte, JJ
机构
[1] CHU LILLE, SERV NEUROL A, LILLE, FRANCE
[2] CHU LILLE, SERV BIOCHIM & BIOL MOL, LILLE, FRANCE
[3] CHU LILLE, SERV PHARMACOL HOSP, LILLE, FRANCE
[4] CHU LILLE, SERV PNEUMOL, LILLE, FRANCE
关键词
idiopathic Parkinson's disease; debrisoquine metabolism; CYP2D6; polymorphism; pharmacogenetic;
D O I
10.1097/00002826-199619030-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We investigated genetic polymorphism of the cytochrome P-450 CYP2D6 gene from white patients with idiopathic Parkinson's disease (IPD). The mutations of the CYP2D6 gene associated with the poor metabolizer (PM) phenotype of the debrisoquine/sparteine polymorphism were analyzed in DNA of 130 IPD patients by a polymerase chain reaction (PCR)-based DNA amplification combined with Xba I restriction fragment length polymorphism (RFLP) analysis in 105 patients. Another mutation located in exon 6 was analyzed by Hha I RFLP in 94 IPD patients. The frequencies of the different CYP2D6 gene mutations were compared to the frequencies in sex- and age-matched white control population with chronic bronchitis. The rate of genotypically defined PM and the frequencies of the different mutations were not significantly different in IPD patients and controls. These results fail to confirm the previously reported results concerning CYP2D6 gene mutations in IPD. These equivocal results might be related to methodologic problems. However, other hypotheses have been suggested: impairment of neuronal CYP 2D6 expression, transient modification of CYP 2D6 phenotype, or linkage of CYP2D6 gene to the candidate gene locus directly involved in IPD.
引用
收藏
页码:213 / 221
页数:9
相关论文
共 46 条
  • [1] HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS
    ALVAN, G
    BECHTEL, P
    ISELIUS, L
    GUNDERTREMY, U
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) : 533 - 537
  • [2] [Anonymous], [No title captured]
  • [3] MUTANT DEBRISOQUINE HYDROXYLATION GENES IN PARKINSONS-DISEASE
    ARMSTRONG, M
    DALY, AK
    CHOLERTON, S
    BATEMAN, DN
    IDLE, JR
    [J]. LANCET, 1992, 339 (8800) : 1017 - 1018
  • [4] PERMANENT HUMAN PARKINSONISM DUE TO 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) - 7 CASES
    BALLARD, PA
    TETRUD, JW
    LANGSTON, JW
    [J]. NEUROLOGY, 1985, 35 (07) : 949 - 956
  • [5] OXIDATIVE POLYMORPHISM OF DEBRISOQUINE IN PARKINSONS-DISEASE
    BENITEZ, J
    LADERO, JM
    JIMENEZJIMENEZ, FJ
    MARTINEZ, C
    PUERTO, AM
    VALDIVIELSO, MJ
    LLERENA, A
    COBALEDA, J
    MUNOZ, JJ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (04) : 289 - 292
  • [6] DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION
    BROLY, F
    GAEDIGK, A
    HEIM, M
    EICHELBAUM, M
    MORIKE, K
    MEYER, UA
    [J]. DNA AND CELL BIOLOGY, 1991, 10 (08) : 545 - 558
  • [7] EXTENSIVE METABOLIZERS OF DEBRISOQUINE BECOME POOR METABOLIZERS DURING QUINIDINE TREATMENT
    BROSEN, K
    GRAM, LF
    HAGHFELT, T
    BERTILSSON, L
    [J]. PHARMACOLOGY & TOXICOLOGY, 1987, 60 (04): : 312 - 314
  • [8] POOR METABOLIZERS OF NICOTINE AND CYP2D6 POLYMORPHISM
    CHOLERTON, S
    ARPANAHI, A
    MCCRACKEN, N
    BOUSTEAD, C
    TABER, H
    JOHNSTONE, E
    LEATHART, J
    DALY, AK
    IDLE, JR
    [J]. LANCET, 1994, 343 (8888) : 62 - 63
  • [9] COMELLA C L, 1987, Neurology, V37, P261
  • [10] LACK OF A RELATIONSHIP BETWEEN THE POLYMORPHISM OF DEBRISOQUINE OXIDATION AND LUNG-CANCER
    DUCHE, JC
    JOANNE, C
    BARRE, J
    DECREMOUX, H
    DALPHIN, JC
    DEPIERRE, A
    BROCHARD, P
    TILLEMENT, JP
    BECHTEL, P
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (05) : 533 - 536